The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Ciliary neurotrophic factor (CNTF) for human retinal degeneration: Phase I trial of CNTF delivered by encapsulated cell intraocular implants
Open accessAbstract
Neurotrophic factors are agents with a promising ability to retard progression of neurodegenerative diseases and are effective in slowing photoreceptor degeneration in animal models of retinitis pigmentosa. Here we report a human clinical trial of a neurotrophic factor for retinal neurodegeneration. In this Phase I safety trial, human ciliary neurotrophic factor (CNTF) was delivered by cells transfected with the human CNTF gene and sequestered within capsules that were surgically implanted into the vitreous of the eye. The outer membrane of the encapsulated cell implant is semipermeable to allow CNTF to reach the retina. Ten participants received CNTF implants in one eye. When the implants were removed after 6 months, they contained viable cells with minimal cell loss and gave CNTF output at levels previously shown to be therapeutic for retinal degeneration in rcd1 dogs. Although the trial was not powered to form a judgment as to clinical efficacy, of seven eyes for which visual acuity could be tracked by conventional reading charts, three eyes reached and maintained improved acuities of 10–15 letters, equivalent to two- to three-line improvement on standard Snellen acuity charts. A surgically related choroidal detachment in one eye resulted in a transient acuity decrease that resolved with conservative management. This Phase I trial indicated that CNTF is safe for the human retina even with severely compromised photoreceptors. The approach to delivering therapeutic proteins to degenerating retinas using encapsulated cell implants may have application beyond disease caused by genetic mutations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Visual Acuity Charts for Clinical Research
Ferris, F. L., Kassoff, A., Bresnick, G. H., & Bailey, I. (1982) · American Journal of Ophthalmology · doi:10.1016/0002-9394(82)90197-0 · Cited by 2,142
Principles and Practice of Ophthalmology
(1981) · American Journal of Ophthalmology · doi:10.1016/0002-9394(81)90081-7 · Cited by 1,073
Photoreceptor degeneration in inherited retinal dystrophy delayed by basic fibroblast growth factor
Faktorovich, E. G., Steinberg, R. H., Yasumura, D., Matthes, M. T., & LaVail, M. M. (1990) · Nature · doi:10.1038/347083a0 · Cited by 710
Standardizatlon of Vitreal inflammatory Activity in Intermediate and Posterior Uveitis
Nussenblatt, R. B., Palestine, A. G., Chan, C.-C., & Roberge, F. (1985) · Ophthalmology · doi:10.1016/s0161-6420(85)34001-0 · Cited by 684
Protection of mouse photoreceptors by survival factors in retinal degenerations.
LaVail, M. M., Yasumura, D., Matthes, M. T., Lau-Villacorta, C., Unoki, K., Sung, C. –., & Steinberg, R. H. (1998) · PubMed · Cited by 537
Retinopathy induced in mice by targeted disruption of the rhodopsin gene
Humphries, M. M., Rancourt, D., Farrar, G. J., Kenna, P., Hazel, M., Bush, R. A., Sieving, P. A., Sheils, D. M., Creighton, P., Erven, A., et al. (1997) · Nature Genetics · doi:10.1038/ng0297-216 · Cited by 529
Self-citationOptical Coherence Tomography of Ocular Diseases
Schuman, J. S., Fujimoto, J. G., Duker, J., & Ishikawa, H. (2024) · CRC Press eBooks · doi:10.1201/9781003525455 · Cited by 484
Neuropoietic cytokines in the hematopoietic fold
Bazan, J. F. (1991) · Neuron · doi:10.1016/0896-6273(91)90258-2 · Cited by 473
A Randomized Trial of Vitamin A and Vitamin E Supplementation for Retinitis Pigmentosa
Berson, E. L. (1993) · Archives of Ophthalmology · doi:10.1001/archopht.1993.01090060049022 · Cited by 465
A Randomized Trial of Vitamin A and Vitamin E Supplementation for Retinitis Pigmentosa
Marmor, M. F. (1993) · Archives of Ophthalmology · doi:10.1001/archopht.1993.01090110018004 · Cited by 459
Cited by
Hartong, D. T., Berson, E. L., & Dryja, T. P. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69740-7 · Cited by 2,924
Gaudana, R., Ananthula, H. K., Parenky, A., & Mitra, A. K. (2010) · The AAPS Journal · doi:10.1208/s12248-010-9183-3 · Cited by 1,406
Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer
Jones, S. A., & Jenkins, B. J. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0066-7 · Cited by 1,102
Hauswirth, W. W., Aleman, T. S., Kaushal, S., Cideciyan, A. V., Schwartz, S. B., Wang, L., Conlon, T. J., Boye, S. L., Flotte, T. R., Byrne, B. J., et al. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.107 · Cited by 954
MacLaren, R. E., Groppe, M., Barnard, A. R., Cottriall, C. L., Tolmachova, T., Seymour, L., Clark, K. R., During, M. J., Cremers, F. P. M., Black, G. C. M., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62117-0 · Cited by 796
Jacobson, S. G. (2012) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2011.298 · Cited by 639
Recent Perspectives in Ocular Drug Delivery
Gaudana, R., Jwala, J., Boddu, S. H. S., & Mitra, A. K. (2009) · Pharmaceutical Research · doi:10.1007/s11095-008-9694-0 · Cited by 605
Perspective on Genes and Mutations Causing Retinitis Pigmentosa
Daiger, S. P. (2007) · Archives of Ophthalmology · doi:10.1001/archopht.125.2.151 · Cited by 467
Engineering the next generation of cell-based therapeutics
Bashor, C. J., Hilton, I. B., Bandukwala, H., Smith, D. M., & Veiseh, O. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00476-6 · Cited by 439
Ocular drug delivery: present innovations and future challenges
Gote, V., Sikder, S., Sicotte, J., & Pal, D. (2019) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.119.256933 · Cited by 441
Biomaterials for promoting brain protection, repair and regeneration
Orive, G., Anitua, E., Pedraz, J. L., & Emerich, D. F. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2685 · Cited by 421
Current and future ophthalmic drug delivery systems
del Amo, E. M., & Urtti, A. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2007.11.002 · Cited by 414
Dias, M. F., Joo, K., Kemp, J. A., Fialho, S. L., da Silva Cunha, A., Woo, S. J., & Kwon, Y. J. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2017.10.004 · Cited by 413
Cuenca, N., Fernández-Sánchez, L., Campello, L., Maneu, V., De la Villa, P., Lax, P., & Pinilla, I. (2014) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2014.07.001 · Cited by 401
Charbel Issa, P., Gillies, M. C., Chew, E. Y., Bird, A. C., Heeren, T. F. C., Peto, T., Holz, F. G., & Scholl, H. P. N. (2013) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2012.11.002 · Cited by 393
Subretinal visual implant alpha IMS - clinical trial interim report
Stingl, K., Bartz-Schmidt, K. U., Besch, D., Chee, C. K., Cottriall, C. L., Gekeler, F., Groppe, M., Jackson, T. L., MacLaren, R. E., Koitschev, A., et al. (2015) · Vision Research · doi:10.1016/j.visres.2015.03.001 · Cited by 387
Retinal remodeling in human retinitis pigmentosa
Jones, B. W., Pfeiffer, R. L., Ferrell, W. D., Watt, C. B., Marmor, M., & Marc, R. E. (2016) · Experimental Eye Research · doi:10.1016/j.exer.2016.03.018 · Cited by 335
Cell microencapsulation technology: Towards clinical application
Murua, A., Portero, A., Orive, G., Hernández, R. M., de Castro, M., & Pedraz, J. L. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.08.010 · Cited by 333
Testa, F., Maguire, A. M., Rossi, S., Pierce, E. A., Melillo, P., Marshall, K., Banfi, S., Surace, E. M., Sun, J., Acerra, C., et al. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2012.11.048 · Cited by 330
Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma
Zhang, K., Zhang, L., & Weinreb, R. N. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3745 · Cited by 316
Zhang, K., Hopkins, J. J., Heier, J. S., Birch, D. G., Halperin, L. S., Albini, T. A., Brown, D. M., Jaffe, G. J., Tao, W., & Williams, G. A. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018987108 · Cited by 310
Self-citationTransplantation of the RPE in AMD
Binder, S., Stanzel, B. V., Krebs, I., & Glittenberg, C. (2007) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2007.02.002 · Cited by 292
Talcott, K. E., Ratnam, K., Sundquist, S. M., Lucero, A. S., Lujan, B. J., Tao, W., Porco, T. C., Roorda, A., & Duncan, J. L. (2011) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.10-6479 · Cited by 276
Self-citationKimberling, W. J., Hildebrand, M. S., Shearer, A. E., Jensen, M. L., Halder, J. A., Trzupek, K., Cohn, E. S., Weleber, R. G., Stone, E. M., & Smith, R. J. H. (2010) · Genetics in Medicine · doi:10.1097/gim.0b013e3181e5afb8 · Cited by 270
Shen, W., Fruttiger, M., Zhu, L., Chung, S. H., Barnett, N. L., Kirk, J. K., Lee, S., Coorey, N. J., Killingsworth, M., Sherman, L. S., et al. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.2841-12.2012 · Cited by 267
Edelhauser, H. F., Rowe-Rendleman, C. L., Robinson, M. R., Dawson, D. G., Chader, G. J., Grossniklaus, H. E., Rittenhouse, K. D., Wilson, C. G., Weber, D. A., Kuppermann, B. D., et al. (2010) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.10-5392 · Cited by 262
Radtke, N. D., Aramant, R. B., Petry, H. M., Green, P. T., Pidwell, D. J., & Seiler, M. J. (2008) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2008.04.009 · Cited by 255
Neuroprotective strategies for retinal disease
Pardue, M. T., & Allen, R. S. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2018.02.002 · Cited by 237
“These studies promoted a clinical trial using encapsulated cell technology with CNTF for human retinal degeneration and demonstrated the safety of this delivery approach and the targeted levels of CNTF output (Sieving et al., 2006).”
Principles of pharmacology in the eye
Awwad, S., Mohamed Ahmed, A. H. A., Sharma, G., Heng, J. S., Khaw, P. T., Brocchini, S., & Lockwood, A. (2017) · British Journal of Pharmacology · doi:10.1111/bph.14024 · Cited by 224
“In a clinical trial, NT-501 was found to reduce photoreceptor degradation in patients with retinitis pigmentosa and improve their objective visual acuity (Sieving et al., 2006).”
Emerging therapies for inherited retinal degeneration
Scholl, H. P. N., Strauss, R. W., Singh, M. S., Dalkara, D., Roska, B., Picaud, S., & Sahel, J.-A. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf2838 · Cited by 219
Garcia, P., Youssef, I., Utvik, J. K., Florent-Béchard, S., Barthélémy, V., Malaplate-Armand, C., Kriem, B., Stenger, C., Koziel, V., Olivier, J.-L., et al. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.4182-09.2010 · Cited by 139
“Although CNTF protects neurons from degeneration arising from multiple etiologies (Duff and Baile, 2003; Sieving et al., 2006), it has not been evaluated in preclinical studies in the context of AD pathology (Emerich and Thanos, 2006).”
Birch, D. G., Bennett, L. D., Duncan, J. L., Weleber, R. G., & Pennesi, M. E. (2016) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2016.07.013 · Cited by 112
Neuroprotection in Glaucoma: Animal Models and Clinical Trials
Almasieh, M., & Levin, L. A. (2017) · Annual Review of Vision Science · doi:10.1146/annurev-vision-102016-061422 · Cited by 111
“The same method was used for sustained delivery of CNTF for six months in a phase 1 human trial of retinal degeneration (Sieving et al. 2006).”
MethodRhee, K. D., Nusinowitz, S., Chao, K., Yu, F., Bok, D., & Yang, X.-J. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1303604110 · Cited by 92
“We constructed a CNTF-expressing lentiviral vector (LV-hCNTF) that carries the cytomegalovirus (CMV) immediate-early promoter followed by a human CNTF cDNA encoding a secreted and modified CNTF identical to that used in the clinical trials (12) (Fig.”
MethodTreatment of ocular disorders by gene therapy
Solinís, M. Á., del Pozo-Rodríguez, A., Apaolaza, P. S., & Rodríguez-Gascón, A. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2014.12.022 · Cited by 88
Advances in gene therapy for diseases of the eye
Petit, L., Khanna, H., & Punzo, C. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.040 · Cited by 82
Identification of a critical sulfation in chondroitin that inhibits axonal regeneration
Pearson, C. S., Mencio, C. P., Barber, A. C., Martin, K. R., & Geller, H. M. (2018) · eLife · doi:10.7554/elife.37139 · Cited by 75
Kang-Mieler, J. J., Dosmar, E., Liu, W., & Mieler, W. F. (2017) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2016.1227785 · Cited by 73
“yet allows nutrients and therapeutic molecules to diffuse freely across the membrane [106,107].”
BackgroundScholl, H. P. N., Moore, A. T., Koenekoop, R. K., Wen, Y., Fishman, G. A., van den Born, L. I., Bittner, A., Bowles, K., Fletcher, E. C., Collison, F. T., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0143846 · Cited by 71
“A number of novel therapies such as gene replacement therapy [32–34] (summarized in [35]) and biological growth factors [36,37] (summarized in [38]) are currently being tested in human clinical trials.”
Hypoxia-regulated retinal glial cell-specific promoter for potential gene therapy in disease
Prentice, H. M., Biswal, M. R., Dorey, C. K., & Blanks, J. C. (2011) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.10-6835 · Cited by 35
ERK1/2 pathway is activated in degenerated Rpe65-deficient mice
Métrailler, S., Emery, M., Schorderet, D. F., Cottet, S., & Roduit, R. (2013) · Experimental Eye Research · doi:10.1016/j.exer.2013.08.015 · Cited by 5
Metadata
- Authors
- Sieving, P. A., Caruso, R. C., Tao, W., Coleman, H. R., Thompson, D. J. S., Fullmer, K. R., & Bush, R. A.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2006-02-27
- Volume
- 103
- Issue
- 10
- Pages
- 3896-3901
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2096993232
- Cited by
- 589
- References
- 48
- FWCI
- 17.19
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.